💡 50% of hires happen without a job posting·⚡ Apply spontaneously to dozens of companies📈 Track opens & CV clicks
NOVADIP Biosciences S.A.
Public profile- Mont-Saint-Guibert, BE
- 51-200 collaborators
- Pharmaceutical/Biotech
- Mont-Saint-Guibert, BE
- 51-200 collaborators
- Pharmaceutical/Biotech
Overview NOVADIP Biosciences S.A.
https://novadip.com/About us
What we do: Novadip Biosciences is a clinical-stage biopharmaceutical company focused on regenerative medicine, specializing in the development of innovative tissue regeneration products for bone and tissue healing. Our lead products include NVD-X3, an allogeneic bone grafting material designed as an 'off-the-shelf' solution for accelerated tissue healing, and NVD-003, an autologous cell-based therapy for congenital pseudarthrosis of the tibia, a rare pediatric bone condition. Our proprietary 3M³ tissue regeneration platform enables the creation of regenerative therapies that address large bone defects, bone non-union, and spine fusion, offering new treatment options for patients with limited alternatives.
Where we are located: Our headquarters are in Mont-Saint-Guibert, Belgium, at Ru Granbonpré 11, 1435. This location serves as the central hub for our research, development, and administrative activities.
Short history: Founded in 2013 as a spin-off from Université Catholique de Louvain (UCLouvain) and St. Luc University Hospital, Novadip Biosciences has advanced rapidly in the field of regenerative medicine. The company is built on the scientific discoveries of founder Prof. Dr. Denis Dufrane, MD, PhD, and has raised €88 million in equity and non-dilutive funding since inception. Novadip targets a total addressable market of $13.5 billion and is preparing for pivotal phase 3 trials for its lead products in the US and EU.
Organization & culture: Novadip Biosciences employs 45 dedicated professionals, fostering a collaborative and innovative environment. Our teams are committed to advancing the standard of care in regenerative medicine, driven by scientific excellence and patient-focused values.
Recent developments: Novadip recently received RMAT designation from the FDA for NVD-003, its regenerative treatment for congenital pseudarthrosis of the tibia. The company has also reported positive interim clinical data for NVDX3 in spine fusion and is preparing for phase 3 trials for NVD-003 in both the US and EU.
Company roles mapping
This mapping combines roles declared by the company and roles identified by artificial intelligence from public data or past job offers. Some job titles are also standardised according to the European ESCO nomenclature (European Skills, Competences, Qualifications and Occupations) to ensure consistency with European skills frameworks. Learn more about AI transparency and ESCO →
- Chief Financial Officer
- Clinical Research Scientist
- Regulatory Affairs Manager
- Quality Assurance Specialist
Employee distribution by work field
Estimate based on public data and company information. Learn more about AI transparency →
